{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:14:01Z","timestamp":1788556441250,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omta.2026.201727","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:09:49Z","timestamp":1775030989000},"page":"201727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of in vitro potency assays for AAV-based gene silencing therapies targeting FSHD and CMT1A"],"prefix":"10.1016","volume":"34","author":[{"given":"Jason","family":"McCoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay M.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Salzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5135-4317","authenticated-orcid":false,"given":"Scott Q.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201727_bib1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-associated defective virus particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201727_bib2","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ymthe.2025.03.064","article-title":"AAV vector development, back to the future","volume":"33","author":"Suarez-Amaran","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201727_bib3","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ymthe.2020.04.007","article-title":"RNAi-Based Gene Therapy Rescues Developmental and Epileptic Encephalopathy in a Genetic Mouse Model","volume":"28","author":"Aimiuwu","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201727_bib4","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201727_bib5","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1016\/j.ymthe.2024.08.009","article-title":"Effective knockdown-replace gene therapy in a novel mouse model of DNM1 developmental and epileptic encephalopathy","volume":"32","author":"Jones","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201727_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.13","article-title":"RNAi-mediated Gene Silencing of Mutant Myotilin Improves Myopathy in LGMD1A Mice","volume":"3","author":"Liu","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omta.2026.201727_bib7","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1172\/JCI130600","article-title":"Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models","volume":"129","author":"Morelli","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.omta.2026.201727_bib8","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1038\/s41467-021-27430-1","article-title":"Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy","volume":"12","author":"Saad","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201727_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159814","article-title":"A translatable RNAi-driven gene therapy silences PMP22\/Pmp22 genes and improves neuropathy in CMT1A mice","volume":"132","author":"Stavrou","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.omta.2026.201727_bib10","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1093\/brain\/awaf125","article-title":"Synaptic dysregulation in a mouse model of GRIN2D developmental and epileptic encephalopathy","volume":"148","author":"Teoh","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.omta.2026.201727_bib11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/mt.2012.68","article-title":"RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy","volume":"20","author":"Wallace","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201727_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2017.12.005","article-title":"Pre-clinical safety and off-target studies to support translation of AAV-mediated RNAi therapy for FSHD","volume":"8","author":"Wallace","year":"2018","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201727_bib13","series-title":"Addressing potency assay-related development delays for cell and gene therapies: Results of a scientific exchange between FDA and developers","first-page":"1","year":"2023"},{"key":"10.1016\/j.omta.2026.201727_bib14","article-title":"Title 21, Chapter 1, Subchapter F - Biologics, Part 600, Subpart A, 600.3 Definitions","year":"2025"},{"key":"10.1016\/j.omta.2026.201727_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22105350","article-title":"Bioassay development for bispecific antibodies-challenges and opportunities","volume":"22","author":"Register","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201727_bib16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1128\/CMR.00008-08","article-title":"Gene therapy using adeno-associated virus vectors","volume":"21","author":"Daya","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.omta.2026.201727_bib17","series-title":"Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products","year":"2011"},{"key":"10.1016\/j.omta.2026.201727_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature16465","article-title":"An essential receptor for adeno-associated virus infection","volume":"530","author":"Pillay","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201727_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2025.13971","article-title":"Delivery of a muscle-Targeted adeno-associated vector via ex vivo normothermic perfusion Is efficient, durable, and safe in a preclinical porcine heart transplant model","volume":"38","author":"Dewan","year":"2025","journal-title":"Transpl. Int."},{"key":"10.1016\/j.omta.2026.201727_bib20","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of Adeno-associated viruses are widely disseminated in human tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201727_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/JVI.72.1.309-319.1998","article-title":"Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2","volume":"72","author":"Rutledge","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201727_bib22","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201727_bib23","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201727_bib24","series-title":"Potency Assurance for Cellular and Gene Therapy Products","year":"2023"},{"key":"10.1016\/j.omta.2026.201727_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn1902","article-title":"The translational gap for gene therapies in low- and middle-income countries","volume":"16","author":"Doxzen","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201727_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drudis.2021.09.001","article-title":"Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues","volume":"27","author":"Young","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omta.2026.201727_bib27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cels.2022.11.005","article-title":"The sound of silence: Transgene silencing in mammalian cell engineering","volume":"13","author":"Cabrera","year":"2022","journal-title":"Cell Syst."},{"key":"10.1016\/j.omta.2026.201727_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.gene.2008.09.033","article-title":"Epigenetic regulation of cytomegalovirus major immediate-early promoter activity in transgenic mice","volume":"428","author":"Mehta","year":"2009","journal-title":"Gene"}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:32:16Z","timestamp":1788553936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26000625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3117387X26000625"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201727","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of in vitro potency assays for AAV-based gene silencing therapies targeting FSHD and CMT1A","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201727"}}